Molecular Partners AG MOLN shares are trading lower again Thursday on continued weakness after the company recently said its partner Novartis expects the FDA may require additional clinical data for the Emergency Use Application for ensovibep.
Vas Narasimhan, Novartis’ CEO, also noted the current omicron wave of SARS-Cov-2, and the lower incidents of hospitalization associated with it, have made clinical investigations challenging to execute in this evolving environment.
Novartis is engaging with the FDA to align on a potential Phase 3 study design that could provide the additional data the agency is seeking for the EUA or full regulatory approval.
See Also: Why Pinterest Shares Are Moving Higher Today
According to data from Benzinga Pro, Molecular Partners has a 52-week high of $32.04 and a 52-week low of $7.99.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
